Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Queensland Health
Mallinckrodt
Boehringer Ingelheim
Farmers Insurance
Federal Trade Commission
Johnson and Johnson
Healthtrust
Cantor Fitzgerald

Generated: June 18, 2018

DrugPatentWatch Database Preview

NEDOCROMIL SODIUM Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Nedocromil Sodium, and what generic alternatives are available?

Nedocromil Sodium is a drug marketed by Akorn and is included in one NDA.

The generic ingredient in NEDOCROMIL SODIUM is nedocromil sodium. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nedocromil sodium profile page.
Drug patent expirations by year for NEDOCROMIL SODIUM
Pharmacology for NEDOCROMIL SODIUM
Medical Subject Heading (MeSH) Categories for NEDOCROMIL SODIUM
Synonyms for NEDOCROMIL SODIUM
4H-Pyrano(3,2-g)quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-, disodium salt
69049-73-6 (Parent)
69049-74-7
Abrevia
AC1L18TW
AK326157
AKOS015909770
Alocril
Alocril (TN)
AN-37980
API0003522
BC202813
C19H16NO7.Na
CHEBI:7493
CHEMBL915
D00527
DISODIUM 9-ETHYL-4,6-DIOXO-10-PROPYL-4H,6H,9H-CHROMENO[7,6-B]PYRIDINE-2,8-DICARBOXYLATE
disodium 9-ethyl-4,6-dioxo-10-propyl-6,9-dihydro-4H-pyrano[3,2-g]quinoline-2,8-dicarboxylate
disodium 9-ethyl-4,6-dioxo-10-propyl-pyrano[3,2-g]quinoline-2,8-dicarboxylate
disodium 9-ethyl-4,6-dioxo-10-propylpyrano[3,2-g]quinoline-2,8-dicarboxylate
disodium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano-[3,2-g]-quinoline-2,8-dicarboxylate
Disodium-9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylate
DTXSID00219115
ET8IF4KS1T
FPL 59002KP
FPL-59002KP
FT-0603491
I14-31884
JQEKDNLKIVGXAU-UHFFFAOYSA-L
LS-127533
Nedocromil sodium (USAN)
Nedocromil sodium [USAN]
PL008390
Rapitil
SCHEMBL24944
Sodium 9-ethyl-4,6-dioxo-10-propyl-6,9-dihydro-4H-pyrano[3,2-g]quinoline-2,8-dicarboxylate
Tilade
Tilade (TN)
Tilarin
Tilavist
TRA0037647
UNII-ET8IF4KS1T
VA11365

US Patents and Regulatory Information for NEDOCROMIL SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akorn NEDOCROMIL SODIUM nedocromil sodium SOLUTION/DROPS;OPHTHALMIC 090638-001 Aug 22, 2012 AT RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Farmers Insurance
Medtronic
McKinsey
Mallinckrodt
Johnson and Johnson
Healthtrust
Queensland Health
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.